Translational Cancer Epidemiology

Translational Cancer Epidemiology Unit

The Translational Cancer Epidemiology Unit was established at the end of 2015. It concentrates on the (further) development and evaluation of strategies for reducing cancer incidence and mortality. In Germany, cancer is the second most common cause of death and more than 480,000 people develop cancer every year.

A third of all cancer cases is thought to be preventable, but the potential of primary prevention is currently not fully exploited. Secondary prevention (early detection) is another promising field, i.e., the detection of cancer at a stage with good prognosis.

In the case of colorectal cancer, the second most common cancer in Germany, early detection has particularly high potential, since the disease generally develops slowly from removable cancer precursors. In addition, effective methods for early detection of colorectal cancer are available (colonoscopy, immunochemical fecal occult blood test). However, further research is needed on how to optimally implement colorectal cancer screening programs at the population level. Current and future research projects of the unit will be devoted to this area. In co-operation with the department "Prevention and Evaluation," the unit also evaluates the mammography screening program in Germany.

In close cooperation with the Bremen Cancer Registry, the unit is working on establishing a further research area on cancer prevention for relatives of cancer patients. In addition, important methodological preliminary work is currently carried out in order to use the German Pharmacoepidemiological Research Database (GePaRD) for cancer-related questions in the future.

Selected Publications

Haug U. Flexible sigmoidoscopy screening for colorectal cancer: Different outcomes in men and women are a challenge for decision makers. BMJ 2017 (Editorial).

Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MC, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended? Gut 2016; in press.

Fiederling J, Shams AZ, Haug U. Validity of self-reported family history of cancer: A systematic literature review on selected cancers. Int J Cancer 2016; 139:1449-60.

Current projects


Binder, Sebastian
Tel.: +49 (0)421 218-56877
Fax: +49 (0)421 218-56941

Eberle, Andrea, Dr.
Tel.: +49 (0)421 218-56962
Fax: +49 (0)421 218-56941

Heinig, Miriam
Tel.: +49 (0)421 218-56881
Fax: +49 (0)421 218-56941

Hornschuch, Michel
Tel.: +49 (0)421 218-56815
Fax: +49 (0)421 218-56821

Kallaene, Carina
Tel.: +49 (0)421 218-56834
Fax: +49 (0)421 218-56821

Kanbach, Josephine
Tel.: +49 (0)421 218-56785
Fax: +49 (0)421 218-56821

Langner, Ingo, Dr.
Tel.: +49 (0)421 218-56867
Fax: +49 (0)421 218-56941

Luttmann, Sabine, Dr.
Tel.: +49 (0)421 218-56961
Fax: +49 (0)421 218-56941

Platzbecker, Katharina, Dr.
Tel.: +49 (0)421 218-56922
Fax: +49 (0)421 218-56941

Rischke, Nikolaj
Tel.: +49 (0)421 218-56885
Fax: +49 (0)421 218-56941

Schäfer, Wiebke
Tel.: +49 (0)421 218-56887
Fax: +49 (0)421 218-56821

Schwarz, Sarina
Tel.: +49 (0)421 218-56884
Fax: +49 (0)421 218-56941

Seebeck, Birte

Streit, Daniela
Tel.: +49 (0)421 218-56784
Fax: +49 (0)421 218-56821

Thiyagarajan, Arulmani
Tel.: +49 (0)421 218-56843
Fax: +49 (0)421 218-56941